Becton Dickinson, Bioscience and Diagnostic Solutions

Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business
Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and allow the company to invest more in innovation and margin growth.
Becton Dickinson to break off biosciences, diagnostic solutions
Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.
Becton Dickinson to Split from Bioscience and Diagnostic Solutions Arms
American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic solutions arms to become
BD Announces Intent to Separate Biosciences and Diagnostic Solutions Business to Enhance Focus, Drive Growth and Unlock Value
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD's Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus and growth-oriented investments and capital allocation for both BD and the separated business and enhance value creation for shareholders.
BD bids farewell to its diagnostic, bioscience divisions with company split
After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest its diagnostic and biosciences businesses as the company near | The “New BD,
Becton looks to separate biosciences and diagnostic solutions after upbeat quarterly results
(This Feb. 5 story has been refiled to correct the name of the unit to biosciences and diagnostic solutions, from life sciences, in the headline and paragraphs 1 and 4) (Reuters) - Becton Dickinson beat expectations for first-quarter results and said its board has authorized a plan to separate its biosciences and diagnostic solutions unit on Wednesday,
Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business
Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.
BD to separate Biosciences and Diagnostic Solutions business
BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology firm, has announced that its board of directors has unanimously authorized a plan to separate BD's Biosciences and Diagnostic Solutions business from the rest of the company.
Becton Dickinson price target raised to $269 from $265 at BofA
BofA analyst Travis Steed raised the firm’s price target on Becton Dickinson (BDX) to $269 from $265 and keeps a Buy rating ...
Becton, Dickinson and Company (BDX) Q1 2025 Earnings Call Transcript
At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...
MedCity News8d
Why Blood is Best: Transforming the Diagnostic Journey for Alzheimer’s Disease
and timely diagnostic solutions. As the number of people living with dementia is estimated to grow to more than 152 million by 2050, substantially impacting low-and middle-income countries ...
health.economictimes.indiatimes10d
Siemens Healthineers unveils advanced diagnostic imaging solutions at AOCR 2025
Showcasing innovative MRI, CT, digital X-ray, and ultrasound systems, Siemens Healthineers aims to redefine diagnostic ...
Becton Dickinson to separate biosciences, diagnostic solutions business
BD announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic ...